Clinical trials to study the efficacy of a novel cardiac viability imaging agent is now underway. FluoroPharma, Inc., an affiliate of QuantRx Biomedical Corp., has developed CardioPET as a means to assess acute and chronic coronary artery disease while patients are at rest.
Entry into Phase I trials follows FluoroPharma's filing with the FDA of an investigational new drug (IND) application for CardioPET, the company's first such application.
